Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Trial Profile

Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2018 Results (n=13) determining the safety, efficacy, and characterize the pharmacodynamic impact of azacitidine + pembrolizumab presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 19 Jan 2018 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top